Literature DB >> 17405118

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

Jennifer S Smith1, Lisa Lindsay, Brooke Hoots, Jessica Keys, Silvia Franceschi, Rachel Winer, Gary M Clifford.   

Abstract

Data on human papillomavirus (HPV) type distribution in invasive and pre-invasive cervical cancer is essential to predict the future impact of HPV16/18 vaccines and HPV-based screening tests. A meta-analyses of HPV type distribution in invasive cervical cancer (ICC) and high-grade squamous intraepithelial lesions (HSIL) identified a total of 14,595 and 7,094 cases, respectively. In ICC, HPV16 was the most common, and HPV18 the second most common, type in all continents. Combined HPV16/18 prevalence among ICC cases was slightly higher in Europe, North America and Australia (74-77%) than in Africa, Asia and South/Central America (65-70%). The next most common HPV types were the same in each continent, namely HPV31, 33, 35, 45, 52 and 58, although their relative importance differed somewhat by region. HPV18 was significantly more prevalent in adeno/adenosquamous carcinoma than in squamous cell carcinoma, with the reverse being true for HPV16, 31, 33, 52 and 58. Among HSIL cases, HPV16/18 prevalence was 52%. However, HPV 16, 18 and 45 were significantly under-represented, and other high-risk HPV types significantly over-represented in HSIL compared to ICC, suggesting differences in type-specific risks for progression. Data on HPV-typed ICC and HSIL cases were particularly scarce from large regions of Africa and Central Asia. Copyright (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17405118     DOI: 10.1002/ijc.22527

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  536 in total

1.  Feasibility study of a human papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and cancer.

Authors:  Johannes Schweizer; Peter S Lu; Charles W Mahoney; Marthe Berard-Bergery; Minh Ho; Valli Ramasamy; Jon E Silver; Arnima Bisht; Yassine Labiad; Roger B Peck; Jeanette Lim; Jose Jeronimo; Roslyn Howard; Patti E Gravitt; Philip E Castle
Journal:  J Clin Microbiol       Date:  2010-10-06       Impact factor: 5.948

2.  Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer.

Authors:  Nancy E Joste; Brigitte M Ronnett; William C Hunt; Amanda Pearse; Erika Langsfeld; Thomas Leete; MaryAnn Jaramillo; Mark H Stoler; Philip E Castle; Cosette M Wheeler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-11-02       Impact factor: 4.254

3.  Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure.

Authors:  Sarah E Coseo; Carolina Porras; Lori E Dodd; Allan Hildesheim; Ana Cecilia Rodriguez; Mark Schiffman; Rolando Herrero; Sholom Wacholder; Paula Gonzalez; Mark E Sherman; Silvia Jimenez; Diane Solomon; Catherine Bougelet; Leen-Jan van Doorn; Wim Quint; Mahboobeh Safaeian
Journal:  Sex Transm Dis       Date:  2011-10       Impact factor: 2.830

Review 4.  [HPV-associated squamous cell carcinogenesis].

Authors:  G Assmann; K Sotlar
Journal:  Pathologe       Date:  2011-09       Impact factor: 1.011

5.  Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practice.

Authors:  Walter Kinney; Barbara Fetterman; J Thomas Cox; Thomas Lorey; Tracy Flanagan; Philip E Castle
Journal:  Gynecol Oncol       Date:  2011-01-26       Impact factor: 5.482

6.  Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program.

Authors:  Nadia Demarteau; Thomas Breuer; Baudouin Standaert
Journal:  Pharmacoeconomics       Date:  2012-04       Impact factor: 4.981

7.  Co-Incidence of Epstein-Barr Virus and High-Risk Human Papillomaviruses in Cervical Cancer of Syrian Women.

Authors:  Hamda Al-Thawadi; Lina Ghabreau; Tahar Aboulkassim; Amber Yasmeen; Semir Vranic; Gerald Batist; Ala-Eddin Al Moustafa
Journal:  Front Oncol       Date:  2018-07-02       Impact factor: 6.244

8.  Does the Syrian population have to wait for the new generation of human papillomaviruses vaccine?

Authors:  Ala-Eddin Al Moustafa; Amber Yasmeen; Lina Ghabreau; Nizar Akil
Journal:  Hum Vaccin Immunother       Date:  2012-10-02       Impact factor: 3.452

9.  Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3.

Authors:  Long Fu Xi; Laura A Koutsky; Philip E Castle; Cosette M Wheeler; Denise A Galloway; Constance Mao; Jesse Ho; Nancy B Kiviat
Journal:  J Natl Cancer Inst       Date:  2009-01-27       Impact factor: 13.506

10.  Single human papillomavirus 16 or 52 infection and later cytological findings in Japanese women with NILM or ASC-US.

Authors:  Shuhei Abe; Kiyonori Miura; Akira Kinoshita; Hiroyuki Mishima; Shoko Miura; Kentaro Yamasaki; Yuri Hasegawa; Ai Higashijima; Ozora Jo; Atsushi Yoshida; Masanori Kaneuchi; Koh-Ichiro Yoshiura; Hideaki Masuzaki
Journal:  J Hum Genet       Date:  2014-02-13       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.